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Corticosteroids are very efficient in the management of va-
sogenic oedema caused by cerebral tumors or CNS infec-
tions, but according to the current evidence-based clinical
practice guidelines (1-2), corticosteroids are not recom-
mended in standard stroke management, even though the
stroke lesions are also often accompanied by formation of
vasogenic oedema. Corticosteroid therapy in stroke man-
agement was generally discarded after the trials which were
made in the last quarter of the 20th century. Based on the
meta-analysis from 8 randomised controlled trials that in-
cluded 466 patients, it was suggested that corticosteroids do
not provide evidence of a beneficial effect on death follow-
ing acute ischemic stroke, and that the obtained results do
not support the routine use of corticosteroids in the man-
agement of acute ischemic stroke. It was emphasized that,
given the possible adverse effects of corticosteroids, the ben-
efits on both the case fatality and functional outcome would
need to be substantial for this treatment to be recommended
(3). The main adverse effects of steroid therapy that may set
off potential positive effects in ischemic cascade or oedema
formation are hyperglycaemia, infections, and gastrointesti-
nal haemorrhage.
Although there is no evidence in favour of the use of corti-
costeroids in stroke management, there are opinions that the
clinical investigations had been prematurely discarded. In
primary intracerebral haemorrhage (ICH), which is charac-
terised by perihematomal oedema formation, there appear to
be only 3 randomized control trials targeting ICH alone, in-
volving only 159 patients (4). The criticism toward the cur-
rent statements is based on the relatively small number of
patients included in the performed clinical trials, unequal
methods and conclusions of the analysed trials, but also on
the results of some animal studies which showed a beneficial
effect of corticosteroids in some experimental stroke models
(4-5). On the other hand, the preclinical studies demon-
strated also some potential harmful effects of corticosteroids,
e.g. decreased inactivation of glutamate, decreased expres-
sion of BDGF and increased neuronal sensitivity on hypoxia
(6). In addition to well known clinical undesirable side-ef-
fects of corticosteroids, these biochemical changes might
counteract the expected positive effects of steroids.
Despite the suggestions that renewed corticosteroid trials in
stroke should be designed, it seems that further large-scale
trials so far cannot be expected.
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